Vir Biotechnology (VIR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VIR Vir Biotechnology

Watchlist

9.260
+1.770+23.63%

Close Nov 1 16:00 ET

9.200
-0.060-0.65%

Post 19:59 ET

1.27BMarket Cap-2586P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates
WSJ15:05 ET
Express News | Vir Biotechnology Shares Are Trading Higher. The Company Reported Q3 Financial Results
Benzinga15:46 ET
Vir Biotechnology Shares Are Trading Higher. The Company Reported Q3 Financial Results.
Benzinga15:46 ET
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
InvestingNov 1 11:01 ET
Vir Biotechnology (NASDAQ:VIR) Shareholders Have Endured a 76% Loss From Investing in the Stock Three Years Ago
Yahoo FinanceNov 1 10:00 ET
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $19
Moomoo NewsNov 1 09:00 ET · Ratings

Comments

QMengColdJoke

Sep 12 10:43

Very displeased cfo pick

$Vir Biotechnology (VIR.US)$ now you wany to sell company. But f you we have 10 dollar per share in equity and that is in cash. Cutting edge science, at least worth 10 dollar. You want to sell right now for how much? 10 dollar? I would sue you if you sell company below 20 dollar.
Firstly of first you need to pump to 20

Trytosaveabit

Sep 9 15:10

Update

$Vir Biotechnology (VIR.US)$ $Sanofi (SNY.US)$ Reuters· 4 mins ago
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

QMengColdJoke

Aug 1 17:05

So no more HIV no more covid?

$Vir Biotechnology (VIR.US)$ Good news is my position in GILD is safe. Sick but hell if you boost price to 20, I’ll love to leave. Oncology is crowded path, bad idea.
your own platform is most valuable and made 2 Billion for the company. You just let people go…

Trytosaveabit

Jun 26 07:17

News

$Vir Biotechnology (VIR.US)$ Vir Biotechnology Receives FDA Ind Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Trytosaveabit

Jun 5 04:45

Update

$Vir Biotechnology (VIR.US)$ Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

Concept

Top Gainers Yesterday

Intraday+1.08%

VIR Vir Biotechnology

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target